MARKET

VRAX

VRAX

Virax Biolabs Group Ltd
NASDAQ
0.1593
-0.0139
-8.03%
After Hours: 0.1594 +0.0001 +0.06% 19:25 03/27 EDT
OPEN
0.1766
PREV CLOSE
0.1732
HIGH
0.1800
LOW
0.1521
VOLUME
352.94K
TURNOVER
--
52 WEEK HIGH
1.350
52 WEEK LOW
0.1521
MARKET CAP
1.18M
P/E (TTM)
-0.1275
1D
5D
1M
3M
1Y
5Y
1D
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 3d ago
Weekly Report: what happened at VRAX last week (0316-0320)?
Weekly Report · 5d ago
Virax Biolabs Group Ltd. COO and Director Nigel William McCracken files initial beneficial ownership statement
Reuters · 03/20 14:43
Virax Biolabs Shareholders Approve Reverse Split, New Charter and 2026 Equity Plan After Adjourned AGM
TipRanks · 03/18 22:00
Virax Biolabs Delays 2025 Annual Shareholder Meeting After Failing to Reach Quorum, Reschedules for March 18, 2026
Reuters · 03/18 21:09
Virax Biolabs Group names director Evan Michael Norton in initial beneficial ownership filing
Reuters · 03/18 20:08
Virax Biolabs CEO Foster James Alexander Cunliffe Files Initial Beneficial Ownership Statement
Reuters · 03/18 20:08
Virax Biolabs Director Iain David Miller Files Initial Beneficial Ownership Statement
Reuters · 03/18 20:07
More
About VRAX
Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The Company is engaged in developing ViraxImmune with the intention of providing an immunology profiling platform that assesses each individual’s immune risk profile against global viral diseases as well as helping with the early diagnosis of post-viral syndromes associated with T cell exhaustion and chronic inflammation. Its product portfolio includes ViraxClear and ViraxVet. ViraxClear offers a range of accurate diagnostic testing kits and machines. ViraxVet offers various rapid and molecular tests for small animal veterinary diagnostics. The Company is initially focused on diseases associated with post-viral syndromes, including SARS-CoV-2, Human Papillomavirus (HPV), Malaria, Hepatitis B, and Herpes (HSV-1).

Webull offers Virax Biolabs Group Ltd stock information, including NASDAQ: VRAX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VRAX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VRAX stock methods without spending real money on the virtual paper trading platform.